LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata

Key Takeaways Eli Lilly received a positive CHMP opinion to expand Olumiant use in adolescents with severe AA.Phase III data showed 42% patients with severe AA achieved at least 80% scalp hair coverage at 36 weeks.Olumiant recorded sales worth $1.01B in 2025; U.S. adolescent decision expected in H2 2026.Eli Lilly (LLY) and Incyte (INCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the approval of the e ...